FDA-approved Hybrid Convergent Procedure for persistent and longstanding AFib — now available on the Gulf Coast in Lake Charles, Louisiana. Avoid the hassle of big academic centers while accessing a two-team, minimally invasive strategy built for complex AFib.
Minimally Invasive • Two-Team Hybrid Strategy • Designed for Persistent & Longstanding AFib
Serving patients locally in Louisiana and across the U.S., Texas–Louisiana Gulf Coast, and international destinations.

Lake Charles resorts and casinos • Concierge hybrid AFib care • Avoid big-city hospital stress while accessing advanced convergent therapy.
If atrial fibrillation has lasted more than 12 months despite medications, it is classified as longstanding persistent AFib. These patients face a very different reality than early or paroxysmal AFib.
Persistent AFib requires a comprehensive epicardial + endocardial strategy—not just another pass with the catheter inside the heart.
If you have been told, “We’ve done all we can,” or “There’s nothing else,” hybrid convergent therapy may offer a different path.
Hybrid convergent therapy combines minimally invasive surgical ablation on the outside of the heart with advanced electrophysiology mapping on the inside. The goal: durable sinus rhythm in patients with longstanding AFib.
By addressing the epicardial substrate on the back wall of the left atrium, this step targets areas often missed by endocardial catheter ablation alone.
This staged, collaborative approach allows the EP team to fine-tune rhythm control and confirm durability of the surgical lesions.
Clinical trials and multicenter registries show:
Hybrid Convergent Outcomes*
At ~2 years in select clinical trials and multicenter registries for persistent AFib.
*Individual results vary. Data summarized from CONVERGE and multicenter registry publications; formal discussion of risks and benefits occurs during consultation.
Our Lake Charles hybrid AFib program is designed around predictable recovery, clear communication, and long-term rhythm success.
Most patients go home within 1–3 days after the surgical portion of the hybrid procedure.
Most patients report mild to moderate discomfort that improves quickly with our enhanced recovery protocols.
In many hybrid programs, 80–90% of patients leave the hospital in sinus rhythm after the convergent procedure.
Hybrid convergent therapy is built for complex, longstanding AFib—including many patients who have been turned down for repeat procedures elsewhere.
We do not turn away complex patients without a complete, individualized evaluation.
We review prior records, imaging, and rhythm data and coordinate with your local cardiologist or EP when appropriate.
We optimize the whole patient before and after surgery—focusing on metabolic health, vascular stability, inflammation, and early detection. This is not just a procedure; it is a rhythm + longevity program.
GLP-1 pathway support and metabolic reset to improve insulin sensitivity and reduce AFib-driving inflammation.
Tight vascular and hemodynamic control to reduce wall stress, stroke risk, and AFib triggers.
Plaque stabilization and lipid strategy to protect coronary circulation and cerebral perfusion.
Anti-inflammatory nutrition and weight management tailored to cardiac and metabolic risk.
Graduated cardiac conditioning programs aligned with rhythm status and structural findings.
Coronary calcium scoring, lung cancer CT when indicated, age-based cancer screening, and sleep apnea evaluation.
Access advanced hybrid AFib convergent therapy without the congestion, cost, and chaos of a big-city medical center. Lake Charles offers a unique blend of resort-level comfort and evidence-based care.
International patients welcome with dedicated coordination and telehealth pre-screening.
Our team will outline travel timing, length of stay, and follow-up options tailored to your situation.

Director, Gulf Coast Hybrid AFib Center, Lake Charles, Louisiana
Dr. Beckles brings more than 30 years of surgical experience to Gulf Coast Hybrid AFib Center, with a career focused on precision surgery, minimally invasive thoracic approaches, and prevention-driven care.
Philosophy: Precision surgery. Metabolic optimization. Longevity medicine. Every convergent procedure is part of a larger plan to extend healthspan, not just suppress an arrhythmia.
Straightforward answers to the most common questions about hybrid convergent therapy, blood thinners, and recovery expectations.
Yes. The convergent procedure platform used in our hybrid AFib program is FDA approved. We follow guideline-based protocols and review all risks and benefits with you before scheduling.
Many patients may qualify to discontinue blood thinners after rhythm stabilization and secure management of the left atrial appendage. This decision is individualized based on your stroke risk score (CHA₂DS₂-VASc), imaging, and shared decision-making with your cardiologist.
You may actually be an ideal candidate. Hybrid convergent therapy was designed precisely for patients with persistent or longstanding AFib who have not responded to catheter ablation alone.
No. The convergent procedure is performed through small incisions using minimally invasive thoracoscopic or robotic approaches. The heart is not stopped and there is no sternotomy.
Most patients are walking the hallway the day after surgery and resume light activity within days. Return to work and heavier activity depends on your baseline health and job type, and is decided collaboratively with your care team.
We operate as an extension of your practice, not a competitor. Our hybrid program is designed for longstanding persistent AFib, redo ablations, and high-risk patients seeking a durable rhythm strategy.
We provide a concise evidence packet you can review or share with your group.
Request the digital packet or schedule a case review conference.
Our program is built on the CONVERGE trial, multicenter registries, and real-world data showing meaningful improvements in rhythm control for longstanding persistent AFib.
Freedom from AFib at ~2 Years*
Illustrative comparison of catheter ablation alone vs. hybrid convergent in persistent / longstanding persistent AFib.
*Representative of published data; not a guarantee of individual outcome. Full trial citations available on request.
Share your history, prior procedures, and current medications. Our AFib team will review your case and coordinate the next best step—locally, nationally, or internationally.
Location: Lake Charles, Louisiana
Phone: (XXX) XXX-XXXX
Dedicated AFib Coordinator: [email protected]
This form is secure and HIPAA-aware. Do not include social security numbers or payment details.
There is another option. Hybrid Convergent Therapy • Lake Charles, Louisiana
Gulf Coast Hybrid AFib Center • Minimally Invasive Convergent AFib Procedure • Lake Charles, Louisiana • Serving Louisiana, Texas, and international patients.